Vadim Sapiro - OpGen Chief Officer
OPGNDelisted Stock | USD 1.90 0.15 7.32% |
Executive
Mr. Vadim Sapiro serves as Chief Information Officer of the Company. He joined the Company in December, 2011 as Chief Information Officer. Mr. Sapiro is responsible for leading the development of the Company bioinformatics applications, software, databases and information technology operations. Prior to OpGen, Mr. Sapiro was senior vice president at SAICFrederick, or SAIC, from June 2008 to December 2011, overseeing the Information Systems Program for the National Cancer Institute at Frederick with responsibility for information technology, scientific computing and bioinformatics. Among Mr. Sapiro projects were technical program management and operations for the cancer Biomedical Informatics Grid, the cancer Human Biobank and The Cancer Genome Atlas . Prior to SAIC, from July 1999 to May 2008, Mr. Sapiro was Vice President for Information Technology with the J. Craig Venter Institute. Mr. Sapiro is active in the regional and national technology and research communities, having served on many life sciences and biotech focused advisory boards and review committees since 2011.
Age | 53 |
Tenure | 14 years |
Phone | 240 813 1260 |
Web | https://www.opgen.com |
OpGen Management Efficiency
The company has return on total asset (ROA) of (0.5224) % which means that it has lost $0.5224 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1492) %, meaning that it created substantial loss on money invested by shareholders. OpGen's management efficiency ratios could be used to measure how well OpGen manages its routine affairs as well as how well it operates its assets and liabilities.OpGen Inc currently holds 13.04 M in liabilities with Debt to Equity (D/E) ratio of 1.11, which is about average as compared to similar companies. OpGen Inc has a current ratio of 1.1, suggesting that it may not be capable to disburse its financial obligations when due. Debt can assist OpGen until it has trouble settling it off, either with new capital or with free cash flow. So, OpGen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OpGen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OpGen to invest in growth at high rates of return. When we think about OpGen's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | EXECUTIVE Age | ||
Dylan John | Neuropace | N/A | |
Lisa Wolf | Tivic Health Systems | 62 | |
Vitaliy Epshteyn | Nuwellis | 46 | |
Susan RN | NeuroMetrix | N/A | |
Meshira Greenberg | Inspira Technologies Oxy | N/A | |
Yafit Tehila | Inspira Technologies Oxy | 42 | |
Michael Soule | Movano Inc | N/A | |
Andrew Cormack | enVVeno Medical Corp | N/A | |
Shmuel Gov | STRATA Skin Sciences | 65 | |
Thomas Stankovich | ReShape Lifesciences | 64 | |
Adi Nir | Inspira Technologies Oxy | N/A | |
Stephen JD | Sight Sciences | N/A | |
Ruth Hembree | Vivos Therapeutics | N/A | |
Brenton Taylor | Sight Sciences | 44 | |
Eryn Graham | Bluejay Diagnostics | N/A | |
Indranil Dey | Bluejay Diagnostics | 62 | |
Sandy Prietto | enVVeno Medical Corp | N/A | |
Amy Treadwell | Neuropace | N/A | |
Irene Thomas | Neuropace | 55 | |
Matthew Link | Sight Sciences | 50 | |
Amir Rippel | NanoVibronix | N/A |
Management Performance
Return On Equity | -3.15 | ||||
Return On Asset | -0.52 |
OpGen Inc Leadership Team
Elected by the shareholders, the OpGen's board of directors comprises two types of representatives: OpGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OpGen. The board's role is to monitor OpGen's management team and ensure that shareholders' interests are well served. OpGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OpGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Albert Weber, CFO Secretary | ||
Michael Farmer, VP Marketing | ||
Honjian Tan, CEO Chairman | ||
Arne Materna, MD GmbH | ||
Terrance Walker, Sr. VP of RandD | ||
Derek Joesting, VP Sales | ||
Vadim Sapiro, Chief Officer | ||
Faranak Atrzadeh, Chief Officer | ||
Theo deVos, MD Genetics | ||
David Lazar, CEO Chairman | ||
Johannes Bacher, Chief Officer | ||
Oliver Schacht, Executive Development |
OpGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is OpGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -3.15 | ||||
Return On Asset | -0.52 | ||||
Operating Margin | (10.13) % | ||||
Current Valuation | 29.68 M | ||||
Shares Outstanding | 8.36 M | ||||
Shares Owned By Insiders | 3.63 % | ||||
Shares Owned By Institutions | 0.26 % | ||||
Number Of Shares Shorted | 13.44 K | ||||
Price To Earning | (0.39) X | ||||
Price To Book | 2.79 X |
Pair Trading with OpGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OpGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OpGen will appreciate offsetting losses from the drop in the long position's value.Moving against OpGen Pink Sheet
0.6 | BDMD | Baird Medical Investment Upward Rally | PairCorr |
0.44 | BSGM | BioSig Technologies, | PairCorr |
0.42 | VASO | Vaso Corp | PairCorr |
0.38 | NMRD | Nemaura Medical | PairCorr |
0.32 | ADMT | Adm Tronics Unltd | PairCorr |
The ability to find closely correlated positions to OpGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OpGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OpGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OpGen Inc to buy it.
The correlation of OpGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OpGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OpGen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OpGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in OpGen Pink Sheet
If you are still planning to invest in OpGen Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OpGen's history and understand the potential risks before investing.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |